Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|September 2, 2019
- Pharmaceutical Technology-09-02-2019
- Volume 43
- Issue 9
Improved Mixer Lift and Seal Designs
Charles Ross & Son Company made improvements to the dual-post hydraulic lift and seal design of its 1500-gallon Multi-Shaft Mixer Model PVM-1500.
Charles Ross & Son Company made improvements to the dual-post hydraulic lift and seal design of its 1500-gallon Multi-Shaft Mixer Model PVM-1500. The new lifting design is a double-acting, fully hydraulic cylinder operating at a higher pressure, allowing for a smaller cylinder and less oil for operation.
The new seal arrangement permits seal replacement without removing agitator shafts. Unlike the previous design, seal replacement no longer requires removal of the mixer from the tank nor tank entry to access the seal.
The PVM-1500 features three independently driven agitators: a screw auger, a high-speed disperser, and a three-wing anchor agitator. The sides and bottom of the changeable mixing vessel are insulated and jacketed for up to 50 psig. According to the company, this vacuum-rated machine can run continuously and is supplied with rugged touchscreen controls showing digital readouts for speed, cycle time, vacuum level, and batch temperature.
Articles in this issue
about 7 years ago
Pharma’s Got Talent?about 7 years ago
The Big Deal Behind the ‘No-Deal’ Scenarioabout 7 years ago
EMA’s Regulatory Impact: Not Yet in its PRIMEabout 7 years ago
Using Digital Tools to Optimize Facility Designabout 7 years ago
The Road to Real-Time Release: At-line NIR Testingabout 7 years ago
Putting NIR to Good Use in Tablet Formulation and Manufactureabout 7 years ago
Mass Flow Controllersabout 7 years ago
Viscosity CIP SystemsRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.